ArticleTranslational cancer research2026

Sacituzumab-govitecan plus pembrolizumab: redefining first-line therapy in PD-L1-positive advanced triple-negative breast cancer.

Wesley Antônio Lopes de Lima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.